These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29579855)

  • 41. Frequency of urinary tract infection in renal transplant recipients and effect on graft function.
    Iqbal T; Naqvi R; Akhter SF
    J Pak Med Assoc; 2010 Oct; 60(10):826-9. PubMed ID: 21381612
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful Renal Transplantation in a Patient with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab in China.
    Sun ZJ; Du X; Su LL; Zhang XD; Wang Y; Ren L; Wang W
    Chin Med J (Engl); 2016 Jun; 129(11):1379-81. PubMed ID: 27231180
    [No Abstract]   [Full Text] [Related]  

  • 43. Atypical hemolytic uremic syndrome.
    Afshar-Kharghan V
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):217-225. PubMed ID: 27913483
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.
    Zimmerhackl LB; Hofer J; Cortina G; Mark W; Würzner R; Jungraithmayr TC; Khursigara G; Kliche KO; Radauer W
    N Engl J Med; 2010 May; 362(18):1746-8. PubMed ID: 20445192
    [No Abstract]   [Full Text] [Related]  

  • 45. Update on evaluating complement in hemolytic uremic syndrome.
    Kavanagh D; Goodship TH
    Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):565-71. PubMed ID: 18089972
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
    Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome.
    Verhave JC; Westra D; van Hamersvelt HW; van Helden M; van de Kar NC; Wetzels JF
    Neth J Med; 2013 Sep; 71(7):342-7. PubMed ID: 24038559
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Atypical hemolytic uremic syndrome caused by primary complement defects].
    Reusz G
    Orv Hetil; 2018 Jun; 159(23):929-936. PubMed ID: 29860884
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atypical Hemolytic-Uremic Syndrome: A Clinical Review.
    Nayer A; Asif A
    Am J Ther; 2016; 23(1):e151-8. PubMed ID: 24681522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Late onset of de novo atypical hemolytic-uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab.
    Juega-Mariño FJ; Sala N; López D; Cañas L; Bonet J; Lauzurica R
    Nefrologia; 2016; 36(3):328-9. PubMed ID: 27012439
    [No Abstract]   [Full Text] [Related]  

  • 51. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor.
    Donne RL; Abbs I; Barany P; Elinder CG; Little M; Conlon P; Goodship TH
    Am J Kidney Dis; 2002 Dec; 40(6):E22. PubMed ID: 12460067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Atypical relapse of hemolytic uremic syndrome after transplantation.
    Olie KH; Florquin S; Groothoff JW; Verlaak R; Strain L; Goodship TH; Weening JJ; Davin JC
    Pediatr Nephrol; 2004 Oct; 19(10):1173-6. PubMed ID: 15300478
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome.
    Wiener Y; Nakhleh RE; Lee MW; Escobar FS; Venkat KK; Kupin WL; Mozes MF
    Clin Transplant; 1997 Jun; 11(3):157-62. PubMed ID: 9193835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tacrolimus-associated hemolytic uremic syndrome: a case analysis.
    Lin CC; King KL; Chao YW; Yang AH; Chang CF; Yang WC
    J Nephrol; 2003; 16(4):580-5. PubMed ID: 14696762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eculizumab for the treatment of atypical hemolytic uremic syndrome recurrence after kidney transplantation associated with complement factor H mutations: a case report with a 5-year follow-up.
    Okumi M; Omoto K; Unagami K; Ishida H; Tanabe K
    Int Urol Nephrol; 2016 May; 48(5):817-8. PubMed ID: 26865178
    [No Abstract]   [Full Text] [Related]  

  • 56. IgA NEPHROPATHY IN PATIENTS RECEIVING A RENAL TRANSPLANT.
    Lemes-Canuto AP; de Sandes-Freitas TV; Medina-Pestana JO; Mastroianni-Kirsztajn G
    J Ren Care; 2015 Dec; 41(4):222-30. PubMed ID: 25819382
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation.
    Sinibaldi S; Guzzo I; Piras R; Bresin E; Emma F; Dello Strologo L
    Pediatr Transplant; 2013 Dec; 17(8):E177-81. PubMed ID: 24118826
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report.
    Merola J; Yoo PS; Schaub J; Smith JD; Rodriguez-Davalos MI; Tichy E; Mulligan DC; Asch W; Formica R; Kashgarian M; Kulkarni S
    Transplant Proc; 2016 Nov; 48(9):3106-3108. PubMed ID: 27932157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients.
    Bagnasco SM; Zachary AA; Racusen LC; Arend LJ; Carter-Monroe N; Alachkar N; Nazarian SM; Lonze BE; Montgomery RA; Kraus ES
    Transplantation; 2014 Feb; 97(4):440-5. PubMed ID: 24531821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Complement as a multifaceted modulator of kidney transplant injury.
    Cravedi P; Heeger PS
    J Clin Invest; 2014 Jun; 124(6):2348-54. PubMed ID: 24892709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.